Posted On: 08/21/2015 7:33:40 PM
Post# of 72447
Some DDs on Prurisol, the forgotten middle child.
http://cellceutix.com/prurisol/#sthash.XUBJwjcQ.dpbs
The preclinical studies used the xenografted SCID mouse model. So how well does this model predict efficacy in humans? Etanercept (Enbrel), the psoriasis drug with +$1B in sales, used the same preclinical model.
“Conclusions: Efficacy of etanercept and ciclosporin could be translated to the psoriasis xenograft SCID mouse model.”
Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model.
http://www.ncbi.nlm.nih.gov/pubmed/22050597
" Taken together, the observations published to dated document consistency regarding the efficacy of established antipsoriatic durgs in the psoriatic SCID mouse model and clinical practise . This has so far been demonstrated for steroids, dihydroxycholecalciferol, and cyclosporina A. With the exception of clobetasol proprionate, all drugs were given systemically. On the other hand, a compound that failed to show sufficient clinical efficacy to validate further development also showed only minimal effects in the psoriasis SCID mouse model. The sole compound where contradicting published data exist is IL-10."
The Psoriasis SCID Mouse Model: A Tool for Drug Discovery?
http://link.springer.com/chapter/10.1007%2F3-540-26811-1_12
Although there are lots of competitions, but the psoriasis market is huge and growing. So Prurisol shouldn't be overlooked if the Phase 2 results are positive.
Psoriasis drug market "to be worth over $7.4B in 2020"
http://www.pharmatimes.com/article/11-11-22/P..._2020.aspx
http://cellceutix.com/prurisol/#sthash.XUBJwjcQ.dpbs
The preclinical studies used the xenografted SCID mouse model. So how well does this model predict efficacy in humans? Etanercept (Enbrel), the psoriasis drug with +$1B in sales, used the same preclinical model.
“Conclusions: Efficacy of etanercept and ciclosporin could be translated to the psoriasis xenograft SCID mouse model.”
Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model.
http://www.ncbi.nlm.nih.gov/pubmed/22050597
" Taken together, the observations published to dated document consistency regarding the efficacy of established antipsoriatic durgs in the psoriatic SCID mouse model and clinical practise . This has so far been demonstrated for steroids, dihydroxycholecalciferol, and cyclosporina A. With the exception of clobetasol proprionate, all drugs were given systemically. On the other hand, a compound that failed to show sufficient clinical efficacy to validate further development also showed only minimal effects in the psoriasis SCID mouse model. The sole compound where contradicting published data exist is IL-10."
The Psoriasis SCID Mouse Model: A Tool for Drug Discovery?
http://link.springer.com/chapter/10.1007%2F3-540-26811-1_12
Although there are lots of competitions, but the psoriasis market is huge and growing. So Prurisol shouldn't be overlooked if the Phase 2 results are positive.
Psoriasis drug market "to be worth over $7.4B in 2020"
http://www.pharmatimes.com/article/11-11-22/P..._2020.aspx
(0)
(0)
